SLC5A2 and obesity disorder: Glucagon-like peptide-1 receptor agonists, dual glucagon-like peptide-1 and gastric inhibitory polypeptide agonists, sodium-glucose cotransporter-2 inhibitors, metformin, pramlintide, and some other drugs are discussed as promising therapeutic agents for the management of obesity and/or insulin resistance in patients with T1D [49,50].